Leigh Syndrome Clinical Trial
Official title:
A Natural History Study of Surfeit Locus Protein 1 (SURF1)-Associated Leigh Syndrome
The purpose of the study is to prospectively and systematically collect standardized clinical information, to describe important features of the disease course of SURF1 deficiency. These include but are not limited to symptomatology, clinical course, and risk factors for severe disease and complications.
Participant eligibility for the study will be determined during a screening period lasting up to 45 days. In-clinic follow visits will occur over several days every 6 months for 2 years from baseline. Thereafter, annual telephone follow-up contact will be conducted for 2 additional years. Thus, the active study duration for each participant will be up to approximately 2 years and the total duration per participant will be approximately 4 years. The study will be conducted in the United States and select sites outside the United States based on incidence data. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04378075 -
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
|
Phase 2/Phase 3 | |
| Completed |
NCT01721733 -
Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome
|
Phase 2 | |
| Completed |
NCT02544217 -
A Dose-escalating Clinical Trial With KH176
|
Phase 1 | |
| Recruiting |
NCT03137355 -
The International Registry for Leigh Syndrome
|
||
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Completed |
NCT02352896 -
Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome
|
Phase 2 | |
| Recruiting |
NCT05554835 -
Global Registry and Natural History Study for Mitochondrial Disorders
|
||
| Withdrawn |
NCT03747328 -
ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
|
Phase 2 |